A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractor
A phase 2 trial of Dexamethasone, Daratumumab, Venetoclax in multiple myeloma, run by AbbVie, active and no longer recruiting.
Overview
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT03314181 by AbbVie, with 156 participants enrolled, started 2018-04-02 and due to reach its primary completion in 2031-05. Interventions recorded: Dexamethasone, Daratumumab, Venetoclax, Bortezomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lena
Shares Daratumumab, Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Multiple myeloma.
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma
Shares Daratumumab, Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Multiple myeloma.
- TrialA Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex)
Shares Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Multiple myeloma.
- TrialStudy of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
Shares Dexamethasone, AbbVie (incl. ImmunoGen, Capstan), Venetoclax, Multiple myeloma.
- TrialChina Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexame
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialJapan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dex
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialOpen-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.
- TrialA Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
Shares Bortezomib, Daratumumab, Dexamethasone, Multiple myeloma.